Details for Patent: 10,286,034

Which drugs does patent 10,286,034 protect, and when does it expire?

Patent 10,286,034 protects VYLEESI (AUTOINJECTOR) and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 10,286,034

Title:	Uses of bremelanotide in therapy for female sexual dysfunction
Abstract:	Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
Inventor(s):	Spana; Carl (West Harrison, NY), Jordan; Robert (Hamilton, NJ), Edelson; Jeffrey D. (Berwyn, PA)
Assignee:	Palatin Technologies, Inc. (Cranbury, NJ)
Application Number:	15/642,772
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,286,034

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes						TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

International Family Members for US Patent 10,286,034

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013337341
Brazil	112015009936
Canada	2890081
China	104755094
China	117860866